These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8135853)

  • 21. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
    Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
    Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
    Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
    Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Johnson SW; Perez RP; Godwin AK; Yeung AT; Handel LM; Ozols RF; Hamilton TC
    Biochem Pharmacol; 1994 Feb; 47(4):689-97. PubMed ID: 8129746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
    Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
    Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
    Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either X-irradiation or cisplatin.
    Bedford P; Shellard SA; Walker MC; Whelan RD; Masters JR; Hill BT
    Int J Cancer; 1987 Nov; 40(5):681-6. PubMed ID: 3679594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
    Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
    Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
    Fram RJ; Woda BA; Wilson JM; Robichaud N
    Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
    Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
    Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
    de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J
    Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
    Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
    Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrastructural morphology and localisation of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy.
    Meijera C; van Luyn MJ; Nienhuis EF; Blom N; Mulder NH; de Vries EG
    Biochem Pharmacol; 2001 Mar; 61(5):573-8. PubMed ID: 11239500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
    Zhen W; Link CJ; O'Connor PM; Reed E; Parker R; Howell SB; Bohr VA
    Mol Cell Biol; 1992 Sep; 12(9):3689-98. PubMed ID: 1380646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.